Expand all sections

Pembrolizumab

Keytruda

Extended indication Head & Neck cancer.
Therapeutic value No judgement
Total cost 5,000,000.00

Product

Active substance Pembrolizumab
Domain Oncology and Hematology
Main indication Head and neck cancer
Extended indication Head & Neck cancer.
Proprietary name Keytruda
Manufacturer MSD
Route of administration Intravenous
Therapeutical formulation Intravenous drip
Budgetting framework Intermural (MSZ)

Registration

Registration route Centralised (EMA)
Expected Registration August 2018
Orphan drug No
Additional remarks Dit is een indicatie-uitbreiding. Al geregistreerd door FDA.

Therapeutic value

Current treatment options Nivolumab, Durvalumab, Tremelimumab
Therapeutic value No judgement
Duration of treatment Not found

Expected patient volume per year

Patient volume

> 100

Market share is generally not included unless otherwise stated.
Additional remarks Geldt voor alle immunotherapieën voor hoofd/hals. NKR 2015: totaal 3202, per stadia: 1) 970; 2) 300; 3) 427; 4) 1189

Expected cost per patient per year

Cost 40,000.00 - 60,000.00
References Medicijnkosten.nl
Additional remarks €3.355,96 per injectieflacon van 4 ml, 25 mg/ml.

Potential total cost per year

Total cost

5,000,000.00

This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.